Immunomodulation and new therapeutic strategies in Lyme borreliosis

Cite This

Files in this item

Checksum: MD5:ae7578ac9f1cc722a4b2b2bbcb30336b

DITERICH, Isabel, 2003. Immunomodulation and new therapeutic strategies in Lyme borreliosis [Dissertation]. Konstanz: University of Konstanz

@phdthesis{Diterich2003Immun-8721, title={Immunomodulation and new therapeutic strategies in Lyme borreliosis}, year={2003}, author={Diterich, Isabel}, address={Konstanz}, school={Universität Konstanz} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:creator>Diterich, Isabel</dc:creator> <dcterms:rights rdf:resource=""/> <dc:language>eng</dc:language> <dspace:isPartOfCollection rdf:resource=""/> <dcterms:hasPart rdf:resource=""/> <bibo:uri rdf:resource=""/> <dcterms:alternative>Immunmodulation und neue Therapiestrategien in der Lyme borreliose</dcterms:alternative> <dc:contributor>Diterich, Isabel</dc:contributor> <dspace:hasBitstream rdf:resource=""/> <dc:rights>terms-of-use</dc:rights> <dcterms:abstract xml:lang="eng">If infection with Borrelia burgdorferi is not treated adequately with antibiotics in an early stage, it may lead to Lyme borreliosis (LB), a chronic multisystemic disorder which is difficult to cure. In some cases the pathogen survives in spite of antibiotic treatments. It is challenging to understand why Borrelia are often not eradicated, although being recognized by the host s immune defense and occasionally inducing a strong inflammatory reaction. Thus, it remains an area of debate how this pathogen persists in human tissues. This question was addressed in the present thesis, examining possible immune evasion mechanisms of Borrelia. We propose that Borrelia modulate the host s immune system in order to evade clearance in the immunologically competent host. Tolerance could represent the mechanism inhibiting host response thereby enabling survival and persistence of the pathogen. Promising results were obtained testing a novel treatment strategy for late stage LB, a combination of Filgrastim as an immunosupportive therapy with antibiotics. The respective clinical trial based on these findings was recently started.</dcterms:abstract> <dcterms:isPartOf rdf:resource=""/> <dcterms:issued>2003</dcterms:issued> <dcterms:available rdf:datatype="">2011-03-24T17:45:57Z</dcterms:available> <dc:format>application/pdf</dc:format> <dc:date rdf:datatype="">2011-03-24T17:45:57Z</dc:date> <dcterms:title>Immunomodulation and new therapeutic strategies in Lyme borreliosis</dcterms:title> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> </rdf:Description> </rdf:RDF>

Downloads since Oct 1, 2014 (Information about access statistics)

Diss_formated_ENDVERSION.pdf 185

This item appears in the following Collection(s)

Search KOPS


My Account